RAPT Therapeutics has been granted a patent for pyrazole pyrimidine compounds that target hematopoietic progenitor kinase 1. The compounds can be used for therapeutic purposes. GlobalData’s report on RAPT Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights RAPT Therapeutics Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on RAPT Therapeutics, Peptide pharmacophores was a key innovation area identified from patents. RAPT Therapeutics's grant share as of February 2024 was 31%. Grant share is based on the ratio of number of grants to total number of patents.

A recently granted patent (Publication Number: US11918582B2) discloses a compound of formula (I) and its pharmaceutically acceptable salts for the treatment of diseases associated with hematopoietic progenitor kinase 1 (HPK1) activity. The compound, when administered to a subject in need, shows potential in treating cancer, particularly when combined with anti-cancer drugs like immune checkpoint inhibitors targeting CTLA-4, PD-1, PD-L1, and other immune regulatory proteins.

The patent also covers various chemical structures and compositions of the compound, providing a detailed framework for potential pharmaceutical formulations. The method outlined in the patent extends beyond cancer treatment to include a range of diseases and disorders such as viral infections, bacterial infections, age-related immune decline, and proliferative diseases other than cancer. The compound's versatility in targeting a wide array of cancers, including brain, skin, breast, prostate, and blood cancers, as well as its potential in addressing infections and immune-related conditions, highlights its significance in the field of pharmaceutical research and development.

To know more about GlobalData’s detailed insights on RAPT Therapeutics, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies